设计,合成和生物评估的印尔修饰的塔莫西芬亲属作为强大的抗癌剂
Berrak Ertugrul1, Abdulmelik Aytatli2,3, Omer Faruk Karatas2,3
1Department of Chemistry, Faculty of Sciences, Ataturk University 25240 Erzurum Türkiye nsarac@atauni.edu.tr.
RSC medicinal chemistry
|July 24, 2023
概括
研究人员通过结合印或氧结构来修改他莫西芬 (TMX),创造了新的抗癌药物. 这些新化合物,特别是醇修饰的塔莫西芬亲属,通过选择性地降低细胞活力,在治疗雌激素受体阳性乳腺癌方面表现有前途.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 药物调制提供了一种增强抗癌活性和降低有效剂量的策略.
- 修改现有的抗癌药物,如他莫西芬 (TMX),可以改善治疗结果.
- 通过将其C-环替换为印或氧支架来探索他莫西芬的结构修饰.
研究的目的:
- 为了合成和评估抗癌潜力的新型醇修饰的塔莫西芬类似物.
- 研究这些新化合物对各种乳腺癌细胞系的疗效.
- 为了确定这些类似物是否可以作为替代他莫西芬用于乳腺癌治疗的替代品.
主要方法:
- 通过电友替代合成醇修饰的他莫西芬衍生物和3,3'-bis(醇) 甲 (BIMs).
- 使用细胞活力测定对乳腺癌细胞系进行抗癌活性评估.
- 评估酶活性和雌激素受体 (ER) 调节的基因表达.
主要成果:
- 与tamoxifen相比,Indole修饰的塔莫西芬类似物,特别是BIM和BIM,表明受体敏感乳腺癌细胞的活力有选择性降低.
- 这些化合物有效地抑制了ER调节基因的表达.
- 在用新型化合物治疗的MCF-7细胞中观察到卡斯帕-8活性增加.
结论:
- 合成的醇修饰的塔莫西芬衍生物具有显著的抗癌潜力,特别是在抗ER阳性乳腺癌方面.
- 这些化合物代表着坦莫西芬在乳腺癌治疗中的有希望的替代品.
- 对这些新型类似物进行进一步的研究可能会导致改善乳腺癌治疗策略.
更多相关视频
相关概念视频
01:28Structure-Activity Relationships and Drug Design
773
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
773
01:25Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K